The Development of Oral Nalbuphine Dosage Form

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate possible responses to pharmacokinetic properties for nalbuphine oral formulations in healthy volunteers.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tri-Service General Hospital
• Treatments: Nalbuphine

Criteria

Inclusion Criteria:

• Normal healthy adult subjects between 20-40 years of age.

• Body weight within 80-120% of ideal body weight. Ideal body weight = (height-80)0.7

• Acceptable medical history and physical examination including:

• Normal chest X-ray and ECG results within six months prior to Period I dosing.

• No particular clinical significance in general disease history within two months prior to Period I dosing.

• Acceptable clinical laboratory determinations without significant deviation from normal values within two months prior to Period I dosing, which includes:

• AST (SGOT)

• ALT (SGPT)

• Gama-GT

• alkaline phosphatase

• total bilirubin

• albumin

• glucose

• BUN

• uric acid

• creatinine

• total cholesterol

• triglyceride(TG)

• Acceptable hematology within two months prior to the study, which includes hemoglobin, hematocrit, red blood cells, MCV, MCH, MCHC, white blood cells, differential white blood cells and platelets.

• Acceptable urinalysis within two months prior to the study, which includes pH, blood, glucose and protein.

• Signed the written informed consent to participate in this study.

Exclusion Criteria:

• Recent history of drug or alcohol addiction or abuse.

• A clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the clinical investigator).

• History of allergic response(s) to nalbuphine or related drugs.

• History of clinically significant allergies including drug allergies or allergic bronchial asthma.

• Evidence of chronic or acute infectious diseases.

• Any clinically significant illness or surgery during the four weeks prior to Period I dosing (as determined by the clinical investigator).

• Taking any drug known to induce or inhibit hepatic drug metabolism within one month prior to the beginning of the study.

• Receiving any investigational drug within one month prior to Period I dosing.

• Taking any prescription medication or any nonprescription medication within two weeks prior to Period I doing.

• Donating greater than 150 ml of blood within two months prior to Period I dosing or donating plasma (e.g., plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.

• Consumption of caffeine, xanthine-containing products (i.e., coffee, tea, caffeine-containing sodas, colas and chocolate, etc.) and/or alcohol at least 48 hours prior to days on which dosing is scheduled and during the periods when blood samples are being collected.

• Any other medical reason as determined by the clinical investigator.

• Patient is pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test at Baseline.